When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
TAK - Ovid's soticlestat successful in mid-stage study in severe forms of childhood epilepsy
Takeda Pharmaceutical Company Limited American Depositary Shares
Ovid Therapeutics (NASDAQ:OVID) and development partner Takeda Pharmaceutical Company (NYSE:TAK)announce positive results from a Phase 2 clinical trial, ELEKTRA, evaluating soticlestat in children with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), rare, treatment-resistant, severe forms of epilepsy.
More news on: Ovid Therapeutics Inc., Takeda Pharmaceutical Company Limited, Healthcare stocks news, Stocks on the move,